Search Results for "insulin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for insulin. Results 131 to 140 of 151 total matches.
See also: Afrezza, Exubera

Rosiglitazone (Avandia) Revisited

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010  (Issue 1333)
, 2010). THIAZOLIDINEDIONES — The thiazolidinediones rosiglitazone and pioglitazone (Actos) are insulin ...
The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).
Med Lett Drugs Ther. 2010 Mar 8;52(1333):17 |  Show IntroductionHide Introduction

Resveratrol

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009  (Issue 1321)
insulin sensitivity, and increased survival. 4 A study in non-obese laboratory mice found no increase ...
Resveratrol is a phytochemical found in the skin of red grapes and in many other plants, including berries, plums and peanuts. As a constituent of red wine, it has been associated with cardioprotective effects. Dietary supplements containing resveratrol are now being widely promoted as antioxidants that can prevent agerelated diseases.
Med Lett Drugs Ther. 2009 Sep 21;51(1321):74-5 |  Show IntroductionHide Introduction

Semaglutide (Ozempic) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
glucose-dependent secretion of insulin, suppress glucagon secretion, slow gastric emptying, and promote ...
In recently published clinical trials, once-weekly subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, has reduced body weight significantly in patients with and without type 2 diabetes when given in addition to lifestyle intervention. Liraglutide (Saxenda), another GLP-1 receptor agonist, has been FDA-approved for chronic weight...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):53-4 |  Show IntroductionHide Introduction

Semaglutide (Wegovy) for MASH

   
The Medical Letter on Drugs and Therapeutics • Oct 13, 2025  (Issue 1739)
hepatic steatosis and insulin sensitivity indirectly by reducing food intake and body weight. They also ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has received accelerated approval from the FDA for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH; previously known as nonalcoholic steatohepatitis [NASH]) with moderate to advanced liver fibrosis in adults. It is the second drug and the first GLP-1 receptor agonist to be approved in the US for treatment of MASH; resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist, was granted accelerated approval for the same indication in 2024.
Med Lett Drugs Ther. 2025 Oct 13;67(1739):161-2   doi:10.58347/tml.2025.1739a |  Show IntroductionHide Introduction

Drugs for Ovulation Induction

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2011  (Issue 1376)
syndrome (PCOS), which is associated with obesity, hyperandrogenism, and insulin resistance. Metformin ...
Infertility occurs in about 15% of couples. About one-third of cases are due to problems with ovulation or other female factors, another third are due to a male infertility factor, and the remaining third are unexplained. In older women, unexplained infertility is probably caused by diminished quality and quantity of oocytes. The first approach to treatment of female-factor infertility generally is the use of drugs that stimulate oocyte production.
Med Lett Drugs Ther. 2011 Oct 31;53(1376):86-8 |  Show IntroductionHide Introduction

Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018  (Issue 1561)
, such as calcium, beta-agonists, and/or insulin with glucose.5 CLINICAL STUDIES — FDA approval of SZC was based ...
The FDA has approved sodium zirconium cyclosilicate (Lokelma – AstraZeneca), an oral potassium binder that exchanges hydrogen and sodium for potassium in the gastrointestinal (GI) lumen, for treatment of non-life-threatening hyperkalemia in adults. Sodium zirconium cyclosilicate (SZC) is the third drug to be approved for this indication; sodium polystyrene sulfonate and patiromer (Veltassa) were approved earlier.
Med Lett Drugs Ther. 2018 Dec 3;60(1561):197-9 |  Show IntroductionHide Introduction

Contrave - A Combination of Bupropion and Naltrexone for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014  (Issue 1455)
circumference, LDL-C, HDL-C, triglycerides, and insulin resistance also improved significantly ...
The FDA has approved a fixed-dose combination of the opioid receptor antagonist naltrexone (ReVia, and others) and the antidepressant and smoking cessation agent bupropion (Wellbutrin SR, Zyban, and others), as Contrave (Orexigen/Takeda) for weight loss. The combination was approved for use as an adjunct to diet and increased physical activity in patients with a body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2 and one or more weight-related comorbidities such as hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled...
Med Lett Drugs Ther. 2014 Nov 10;56(1455):112-4 |  Show IntroductionHide Introduction

Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003  (Issue 1169)
-term use will be less likely to cause the lipodystrophy and insulin resistance seen with other PIs ...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Med Lett Drugs Ther. 2003 Nov 10;45(1169):90-2 |  Show IntroductionHide Introduction

Pharmaceutical Drug Overdose

   
Treatment Guidelines from The Medical Letter • Sep 01, 2006  (Issue 49)
. The adverse effects of glucagon include vomiting, hyperglycemia and hypokalemia. 14 High-dose insulin ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Treat Guidel Med Lett. 2006 Sep;4(49):61-6 |  Show IntroductionHide Introduction

Coenzyme Q10

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006  (Issue 1229)
(coenzyme Q10) treatment on glycaemic control, insulin requirement and wellbeing in patients with Type 1 ...
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Med Lett Drugs Ther. 2006 Feb 27;48(1229):19-20 |  Show IntroductionHide Introduction